Population pharmacokinetics and pharmacodynamics ofBYL719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies
Key Points
Key points are not available for this paper at this time.
Abstract
The proposed model provides a valuable approach for planning future clinical studies and for designing optimized dosing regimens with BYL719.
KI fragen
Like
Bookmark
Share
View Full Paper
KI fragen
Like
Bookmark
Share
View Full Paper
Population pharmacokinetics and pharmacodynamics ofBYL719, a phosphoinositide 3‐kinase antagonist, in adult patients with advanced solid malignancies | Synapse